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Abstract
Background: Prospero-related homeobox 1 (Prox1) transcription factor was described as a
tumor-suppressor gene in liver tumors. In contrast, Prox1 knock out in murine embryos drastically
reduces proliferation of hepatoblasts.
Methods: We have studied the expression of Prox1 in normal liver, liver cirrhosis and peritumoral
liver samples in comparison to hepatocellular (HCC) and cholangiocellular carcinoma (CCC) at
mRNA, protein and functional levels.
Results: Prox1 was found in hepatocytes of normal liver, while normal bile duct epithelial cells
were negative. However, Prox1+ cells, which co-expressed biliary epithelial makers and showed
ductular morphology, could be detected within fibrotic septa of cirrhotic livers, and in both HCC
and CCC. Two Prox1 mRNA isoforms (2.9 kb and 7.9 kb) were identified with a prevalence of the
longer isoform in several HCC samples and the shorter in most CCC samples. Evidence was
provided that Myc-associated zinc finger protein (MAZ) might significantly contribute to the gene
expression of Prox1 in HCC, while neo-expression of Prox1 in CCC remains to be resolved. A
point mutation in the prospero domain of Prox1 was found in one HCC sample.
Conclusion: Our study shows dysregulation of Prox1 in liver cirrhosis, HCC and CCC, such as
neo-expression in cells with biliary epithelial phenotype in liver cirrhosis, and in CCC. Altered
Prox1 mRNA expression is partly regulated by MAZ, and mutation of the prospero domain in HCC
indicates an involvement for Prox1 during tumor progression.
Background
Homeobox genes encode transcription factors that con-
trol cell differentiation and play essential roles during
embryonic development [1,2]. The homeobox genes Hlx
[3], Hex [4] and the prospero-related homeobox 1
(Prox1) [5] are involved in the development of the liver
bud. Prox1 belongs to the earliest markers of mammalian
foregut endoderm cells, where its expression is confined
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to a short segment that gives rise both to the liver and pan-
creas, remaining expressed during the adulthood [6,7]. In
Prox1-deficient mice, the hepatoblasts fail to migrate into
the neighboring mesenchyme [8]. Prox1-null mice die
around embryonic day (ED) 14.5 and show a 70% reduc-
tion of liver size [8]. Besides albumin and α-fetoprotein
(AFP), Prox1 is an early marker of hepatoblasts [9]. In our
previous study it was shown that Prox1 remains a stabile
marker of hepatocytes in normal adult, injured and regen-
erating liver, whereas it is not detectable in biliary epithe-
lial cells [10]. Prox1 was found to regulate metabolic
function in hepatocytes, and to be involved in the regula-
tion of other transcription factors [11].
A previous study showed various levels of prox1 mRNA
expression in HCC cell lines and tumor samples [12], and
found that, patients with higher expression had much
more favorable prognosis than those with lower expres-
sion. On the other hand, there was no statistically signifi-
cant difference in the disease-free survival rates between
high and low expression of prox1.
A down-regulation of prox1-gene-expression was reported
in HCC and CCC liver samples compared to normal liver
[12,13]. It was supposed that downregulation of prox1-
gene-expression was induced by the methylation of the
Prox1-promoter [13]. Additionally, so far, no mutations
were found in the coding region of Prox1 in HCCs [12].
However, comparing the gene expression pattern or prox1,
a decreased expression could be found in the average of
HCC and CCC liver samples, whereas, a stable high
expression level persists in HCC cell lines, and in the MZ-
Cha2 biliary adenocarcinoma cell line.
Aim of the current study was to investigate the regulatory
changes of Prox1-gene-expression in liver cirrhosis, in
hepatocellular and cholangiocellular carcinomas. While,
as we recently reported, no Prox1-expression was found in
biliary epithelial cells of the normal liver [10], it was
newly expressed in ductular cells showing biliary epithe-
lial cell makers within the fibrotic septa of cirrhotic livers,
in HCC and CCC. In this study, an altered regulation of
Prox1-gene-expression is described in pathological proc-
esses of the liver.
Methods
Materials
Chemicals were purchased from Merck (Darmstadt, Ger-
many), Applichem (Darmstadt, Germany) or Sigma
(Steinheim, Germany). Materials for biochemical and
immunohistochemical methods are listed in the appro-
priate sections.
Liver Specimens
54 liver surgical specimens (16 peritumoral liver samples
(cirrhotic and non-cirrhotic), 11 cirrhotic liver samples
(without tumor), 19 HCC and 8 CCC) were used. 4 nor-
mal liver specimens were received from internal tissue
bank archives. Informed consent was obtained from each
patient included in the study and the study protocol con-
forms to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the institu-
tion's human local ethics committee.
Cell lines, culture conditions
Hepatocellular carcinoma cell lines: HepG2 (purchased
from the American Tissue Culture Collection (ATCC, Hei-
delberg, Germany)), HuH7 [14] and Hep3B (ATCC), were
cultured conventionally in Dulbecco's MEM (Biochrom,
Berlin, Germany) supplemented with 4.5 g/L glucose,
antibiotics, 2 mM L-glutamine and 10% Fetal Calf Serum
(PAA, Pasching, Austria). SK-ChA1, Mz-ChA1 and Mz-
ChA2 biliary adenocarcinoma cell lines were received
from Prof. A. Knuth (University Hospital, Zurich, Switzer-
land) [15] and were cultured in Dulbecco's MEM contain-
ing 4.5 g/L glucose and 3.7 g/L NaHCO3 supplemented
with antibiotics, 2 mM L-glutamine, 1 mM Na-Pyruvate
and 10% Fetal Calf Serum (PAA, Pasching, Austria).
RNA isolation, northern blot analysis, real time RT-PCR
RNA was isolated with Trizol (Invitrogen, Carlsbad, CA,
USA) from snap-frozen human liver specimens, cultured
hepatoma and biliary adenocarcinoma cells, according to
the instructions of the manufacturer. For northern blot
analysis total RNA was separated by agarose gel electro-
phoresis, transferred onto a nylon membrane and hybrid-
ized with specific α32P-dCTP labeled (Amersham,
Buckinghamshire, UK) cDNA probes (which were labeled
with nick translation or random priming). Human Prox1
specific cDNA probe was kindly provided by Dr. SI.
Tomarev [16], the 18S specific probe was synthesized
using primers described elsewhere [17].
Reverse transcription of mRNA samples was performed
with Mouse-Mammary Leukemia Virus Reverse-Tran-
scriptase (Invitrogen), using random hexamers, according
to the instructions of the manufacturer. Real-time RT-PCR
analysis of cDNA- transcripts was performed with the Abi
Prism Sequence Detection System 7000 of Applied Biosys-
tems (Foster City, CA, USA) following the manufacturer's
instructions, using Sybr-Green reaction master mix (Invit-
rogen) and the primers summarized in Table 1. RT-PCR
for detection of Prox1 mRNA isoforms using exon- and
isoform- specific primers was performed with the Go-Taq
DNA Polymerase Master Mix (Promega, WI, USA) in a
Perkin-Elmer Cycler (Waltham, MA, USA), using primers
described in Fig. 1, and Additional file 1. Primers were
designed based on sequence information provided by theBMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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Vertebrate Genome Annotation [VEGA] database (Cam-
bridge, UK). Gene specific primers for 18S rRNA, Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), beta-
actin and beta-2-macroglobulin were designed as
described previously [17]. Primers were synthesized by
MWG Biotech (Ebersberg, Germany) or by Invitrogen.
The comparative Ct method was used for analysis: the
quantity of the PCR products was determined based on
the threshold PCR cycle-values, and it was normalized
with the quantities of the endogenous control PCR prod-
uct, samples were analysed in triplets [17,18]. The nor-
malised expression levels in all samples were related to the
average normalised expression level in the normal liver, as
a reference. Statistical significance was tested with Mann-
Whitney "U"-test and one-way ANOVA. Several PCR
products were sequenced by Seqlab (Göttingen, Ger-
many), and the sequences were aligned by BLAST analysis
(National Library of Medicine, Bethesda, MD, USA).
4 endogenous controls were tested whether they could be
valuable for the normalisation of the Prox1 expression
levels: the average expression of beta-actin, beta-2-mac-
roglobulin and glycerinaldehyde-3-phosphate dehydro-
genase (GAPDH) genes in HCC, CCC and cirrhotic liver
samples were 1.65 – 2.06 fold increased compared to nor-
mal liver. This increase was significant by Mann-Whitney
"U"-test. Meanwhile, 18S rRNA quantities did not show
significant differences among the examined liver samples.
Therefore, this was used for normalisation of Prox1 and
other mRNA quantities.
Immunostaining of cryosections
Liver sections of 5 µm thickness were cut with a cryostat
(Reichert Jung, Wetzlar, Germany) air-dried for 10 min-
utes and used for immunohistochemical stainings after 10
minutes of acetone fixation at room temperature [10]. The
following primary antibodies were used in the study: rab-
bit polyclonal: anti-Prox1 (1:200; Reliatech, Braunschweig,
Double-stranded oligonucleotide sequences designed for EMSA Figure 1
Double-stranded oligonucleotide sequences designed for EMSA. 5'untranslated sequences (5'-UTR) of the 7902 bases 
and of the 2929 bases transcript isoforms: green sequences are sense, black sequences are antisense. The MAZ-binding site 
was labelled in yellow. MAZ-binding site was not detected in the 5'-UTR of the "Prox1-2929"-transcript. MAZ-binding-site 
from data bank: CACGAGGGGAAG; in the 5'-UTR of the Prox1-7902-transcript the binding site is lying in reverse position. 
In this figure the double-stranded oligonucleotide sequences are described, which were used in this study. (Literature refer-
ence: [23]; database reference: Ensembl Gene Report, OTTHUMG00000036946).BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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Germany), anti-Lyve-1 (1:500, Reliatech) and anti-Podo-
planin (1:500, Reliatech).Mouse monoclonal: anti-Cytoker-
atin (CK) 7 (1:50, DAKO), anti-Cytokeratin (CK) 19
(1:100; Novocastra, Newcastle upon Tyne, England), anti-
HepPar1 (clone: OCH1E5; 1:50; DAKO) and anti OV-6
(1:20; R&D Systems, Minneapolis, MN, USA). The rabbit
polyclonal antibodies were detected with an Alexa-555-
conjugated goat-anti-rabbit secondary antibody (Molecu-
lar Probes, Leiden, Netherlands). Mouse monoclonal
antibodies were visualized with an Alexa-488-conjugated
secondary anti-mouse antibody (Molecular Probes),
diluted 1:200 in PBS. Sections were counter-stained with
DAPI (Molecular Probes) and observed with an epifluo-
rescence microscope (Axiovert 200 M, Zeiss, Jena, Ger-
many). Negative control immunostainings were
performed by omission of the primary antibody, by usage
of a non-immune serum and by usage of isotype-match-
ing control immunoglobulins.
Isolation of cell nuclear extracts, western blot analysis
Cell nuclear proteins were extracted from cultured cells,
and also from human liver tissue, as described before
[19,20]. Ten microgram protein-containing nuclear
extract samples were processed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions [21]; followed by electroblotting
[22]. The detection was performed according to the ECL
protocol (Amersham, Buckinghamshire, England). Pri-
mary rabbit polyclonal antibody against Prox1 (Reli-
atech) was used at 5 µg/ml and primary monoclonal
antibody against HNF4-alpha (Santa Cruz Biotech, Sanata
Cruz, CA, USA) was used at 4.8 µg/ml concentration.
Electrophoretic mobility shift assay (EMSA)
Double-stranded Myc-associated zinc finger protein
(MAZ)-binding consensus- and control- oligonucleotides
were designed based on a previous report [23]. Double-
stranded oligonucleotides (described on Fig. 1; [23]) were
labelled with [γ-32P]ATP (Amersham) using T4 polynucle-
otide kinase (Promega, Mannheim, Germany). Binding
reactions were performed in a volume of 20 µl, compris-
ing 10 µl of 2×-binding buffer (40 mM Hepes, 50 mM
NaCl, 1 mM EDTA, 1 mM dithiothreitol and 0.5 mM
PMSF, pH 7.5,) containing 5 µg of nuclear proteins, 300
ng of polydI-dC, 5 fmol 32P-end-labeled double-stranded
oligonucleotide (8000 c.p.m.) [20]. For competition
experiments a 100-fold molar excess of unlabeled double-
stranded oligonucleotides was included in the DNA bind-
ing reaction [20,23]. Incubation was carried out at room
temperature for 30 min [20], for supershift analysis at 4°C
for overnight, using 2 µl of goat polyclonal anti-MAZ anti-
body (Santa Cruz); 3 µl loading buffer (50% glycerol, 1
mg/ml BSA) was added prior to loading on a 4% non-
denaturing gel in 0.5× TBE buffer. Electrophoresis was
performed at 170 V (in a Bio-Rad Protean II chamber
(Bio-Rad, München, Germany)) for 110 min at 4°C. The
gel was dried and autoradiographed [20].
RNA silencing
The functional role of MAZ in the regulation of prox1-
gene-expression was analyzed by transfection of HepG2
cells with pre-designed MAZ-specific siRNA reagents (siG-
ENOME ON-TARGETplus SMARTpool duplex (Dhar-
macon-Perbio, Bonn, Germany) according to the
instructions of the provider. As negative controls: Mock-
transfection (no siRNA), and non-specific control siRNA
(Cyclophilin B pool) were used. As positive control for the
transfection siGLO Red Transfection Indicator was
applied (Dharmacon-Perbio). 48 hours after the transfec-
tion (following the intructions of the provider) total RNA
was isolated from the transfected cells, it was reverse tran-
scribed, and analyzed by real time PCR using human
Prox1 and MAZ-specific primers described in Table 1.
Table 1: Summary of the primers designed and used in the study.
Gene Forward primer Reverse Primer Amplicon length mRNA location
Human Prox1 (Exon 3–4) 5'-GCT CCA ATA TGC TGA AGA 
CC-3'
5'-ATC GTT GAT GGC TTG ACG 
TG-3'
120 bp 2399–2519
Human HNF4α 5'-GGG GTA CCC ATG GCC 
GAC TAC AGT G-3'
5'-GGG GTA CCG CGC TGA 
CAC CCA GGC TG-3'
140 bp 122 – 262
Human albumin 5'-CTG TGG GGC ACT TTT GAA 
AT-3'
5'-AAC ATC CCC TTC ACA GCA 
TC-3'
154 bp 698 – 851
Human CREB 5'-GAC ACC AGC TGG AGA 
AGG AC-3'
5'-CTT CTT GGT GTC CCA TGC 
TT-3'
198 bp 500 – 698
Human AP-4 5'-GTG CCC TCT TTG CAA CAT 
TT-3'
5'-CTG CCT TGC TGA GCT TCT 
CT-3'
229 bp 289 – 517
Human N-myc 5'-GAC TGT AGC CAT CCG 
AGG AC-3'
5'-GTT TTA ATA CCG GGG GTG 
CT-3'
161 bp 92 – 253
Human MAZ 5'-TAC CAC CTG AAC CGA CAC 
AA-3'
5'-GCT GCC TCA CAT TTC TCA 
CA-3'
247 bp 1040 – 1287BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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Results
Analysis of Prox1 immunohistochemical localization in 
normal human liver, in liver cirrhosis, in HCC and in CCC
In normal human livers, Prox1-antigen was found in the
nuclei of HepPar1+ hepatocytes (Fig. 2A). Prox1 immuno-
histochemical reaction showed a homogeneous distribu-
tion in the liver parenchyma along with the HepPar1-
staining, whereas CK-7+ bile ducts were negative (Fig. 2A–
B).
Hepatocytes within the so-called "regenerative nodules"
of cirrhotic livers showed a strong Prox-1+ immunohisto-
chemical reaction (Fig. 2C). However, Prox1+ cells with a
ductular morphology were detected around regenerative
nodules and within the fibrotic septa. Surprisingly, posi-
tive immunofluorescent reactions with antibodies
described as biliary-type cytokeratins (CK) [24-28], i.e.
CK-7, CK-19 and OV-6 were detected in the cytoplasm of
these cells (Fig. 2C–F). Negative staining for HepPar1
revealed that these cells are not hepatocytes (data not
shown). It was previously described that Prox1 is
expressed in lymph endothelial cells. For this reason we
applied markers of lymph epithelial cells in order to
exclude reactions with lymph endothelium (LYVE-1 and
podoplanin) [29]: these markers did not show co-localisa-
tion with Prox1 (data not shown).
Immunohistochemical analysis of Prox1 in normal human liver, in cirrhotic livers and in hepatocellular carcinoma Figure 2
Immunohistochemical analysis of Prox1 in normal human liver, in cirrhotic livers and in hepatocellular carci-
noma. A) Double immunofluorescent labeling of HepPar1 (green), Prox1 (red) and cell nuclear counterstaining with DAPI 
(blue) in normal human liver shown combined. A: Arteria, B: Bile duct, V: Vena. Bars represent 100 µm. B) Increased magnifi-
cation of a bile duct within a normal human liver. Double immunostaining was performed with anti-CK7 (green) and anti-Prox1 
(red). The blue staining with DAPI represents the nuclei. Bars represent 100 µm. C) Immunohistochemical staining of a regen-
erative nodule in a cirrhotic liver with anti-CK7 (green), anti-Prox1 (red) antibodies and cell nuclear counterstaining with DAPI 
(blue), shown combined. Bars represent 100 µm. D) Double immunostaining of CK7 (green) and Prox1 (red) in ductular cells 
within a fibrotic septum of a cirrhotic liver, cell nuclear counterstaining with DAPI (blue) shown combined. Bars represent 100 
µm. E) Double immunostaining of CK19 (green) and Prox1 (red), cell nuclear counterstaining with DAPI in cells with a ductular 
phenotype within a cirrhotic liver shown combined. Bars represent 100 µm. F) Immunohistochemical reactions of OV-6 
(green) and anti-Prox1 (red) antibodies in HCC and the fibrous septa. The blue staining with DAPI represents the nuclei. 
Prox1+ hepatocytes within the neoplastic nodule are surrounded by OV-6+ ductular cells. Note that OV-6+ cells are simultane-
ously Prox1+ (white arrows). Bars represent 100 µm.BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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In HCC, cells within the neoplastic nodule showed Prox1+
nuclei (Fig. 2F), and similarly to the cirrhotic liver, double
Prox1+/OV-6+ cells were detected in the fibrotic septa sur-
rounding the neoplastic nodules. In CCC, ductular cells
with remarkable Prox1-positivity were detected (Fig. 3A–
B). These cells strongly reacted with anti-OV-6 (Fig. 3A) or
with anti-CK19 (Fig. 3B), but not with HepPar1 (data not
shown) and displayed a cuboid epithelial morphology.
Analysis of prox1-gene-expression in HCC and biliary 
adenocarcinoma cell lines, in normal-, cirrhotic- liver, in 
HCC and CCC tissues
Using northern blot hybridisation more mRNA isoforms
of Prox1 were found. Two of these isoforms were
expressed in normal human liver, liver cirrhosis, in HCC
and in CCC (Fig. 4B; Fig. 5C). The shorter isoform domi-
nated in cirrhotic liver samples and in CCC, while the
longer isoform was more abundant in HCC (Fig. 4B). The
existence of other isoforms could not be excluded, but
they were not clearly determined by hybridisation and
sequencing in this study.
Human HCC cell lines (HepG2, HuH7 and Hep3B)
showed high Prox1 expression, which was detected both
at mRNA and protein levels (Fig. 4A,C). In all of the three
cell lines both of the mRNA isoforms were detected, the
quantitative relationship between those isoforms was dif-
ferent, i. e. HuH7 showed mainly the shorter, while
Hep3B contained more of the longer isoform than of the
short one (Fig. 4A). All of the three cell lines contained the
same 95 kD Prox1 protein in their cell nuclear extract,
HuH7 showed less Prox1-protein than HepG2 and Hep3B
(Fig. 4C). No significant detection of Prox1-protein was
found in the cytoplasmatic-extracts of these cells (not
shown). These data imply the synthesis of a single protein
from more mRNA isoforms.
At mRNA level, high Prox1-expression was detected in the
biliary adenocarcinoma cell line MZ-Cha2 (Fig. 4A) as
described before [13]. Interestingly, only the shorter form
of Prox1 was expressed in MZ-Cha2 (Fig. 4A).
Prox1 mRNA expression was quantified by real-time RT-
PCR using primers designed for a boundary sequence of
exons 3–4 (Table 1), at similar location as it was described
previously [12]. There was no significant difference in the
average Prox1 mRNA expression level in normal liver, in
non-cirrhotic or cirrhotic peritumoral liver, in liver cirrho-
sis, in HCC and in CCC compared to normal human liver,
or compared with each other (p = 0.7932, with One-way
ANOVA, Figure 5A, Table 2). A striking feature of Prox1
mRNA expression in all samples was a high variance (Fig.
5A). In liver cirrhosis and HCC several samples showed
lower Prox1 mRNA expression compared to the average of
the normal liver. Nevertheless, some samples of HCC and
cirrhotic liver showed a higher Prox1 mRNA expression
than the average of the normal liver (Fig. 5A). For more
appropriate analysis individual investigation of some
samples was required. More samples are shown individu-
ally on Fig. 5. Notably, one HCC sample showed an unex-
Double immunostaining of Prox1 (red) with OV-6 or CK19 (green) in intrahepatic cholangiocellular carcinoma Figure 3
Double immunostaining of Prox1 (red) with OV-6 or CK19 (green) in intrahepatic cholangiocellular carci-
noma. (A) OV-6; (B) CK19 show duct-like glandular or acinar structures localised within a dense fibrous stroma. Note that 
the cells are positive for OV-6 or CK19 and for Prox1. The blue colour staining with DAPI represents the nuclei. Bars repre-
sent 100 µm.BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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pected high Prox1-mRNA-expression, which was labelled
with H1.
Comparing Prox1 mRNA expression with differentiation
grade in HCC, no significant difference could be found (p
= 0.693, with One-way ANOVA, Fig. 5B).
In addition, correlation between albumin and Prox1
mRNA expression was analysed. Although, Prox1 expres-
sion levels significantly correlated with albumin levels in
liver cirrhosis (p = 0.04, by correlation analysis, r2  =
0.2717), no correlation could be detected in HCC (not
shown).
The HCC samples, which showed higher mRNA expres-
sion than the average of normal liver were also analysed
with northern blot (Fig. 5C, left panel). This method was
the only way to demonstrate the Prox1-isoforms. Simi-
larly to the real-time PCR data, the northern blot also
showed variability of the Prox1-mRNA-expression in
HCC. In samples H2 and H5 the dominance of the
"Prox1-7902" isoform was detected. It is worthy to note
the increased expression in H1 compared to the other
samples.
All CCC samples were analysed by northern blot. In C1,
C4–5 and C7–8 the dominance of the "Prox1-2929" iso-
form was detected (Fig. 5C, right panel).
Compared to the HCC cell lines, the cell nuclear extracts
of HCC and CCC samples showed lower protein expres-
sion, and protein degradation products (Fig. 5D). Unfor-
tunately, the H1 sample was not available any more for
protein analysis.
Using primers described in Table 1 and in Additional file
1, mutation analysis was performed in all cDNA samples
used in the study. Interestingly, the H1 sample (Fig. 5),
with unexpectedly high Prox1 expression contained a
point-mutation, which was detected using the primers
Northern and western blot of Prox1, in normal liver, in liver cirrhosis in HCC and in CCC Figure 4
Northern and western blot of Prox1, in normal liver, in liver cirrhosis in HCC and in CCC. (A) Prox1 mRNA and 
28s rRNA analysis on a northern blot of HCC cell lines (Hep3B, HepG2 and HuH7), and in a biliary adenocarcinoma cell line 
(Mz-Cha2). (B) Prox1 mRNA and 28s rRNA on a northern blot of human liver samples (normal liver, liver cirrhosis, HCC and 
CCC). Individual samples are labelled as on Figure 5.(C) Prox1 and HNF4-alpha western blot in HCC cell lines.BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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Quantitative analysis of Prox1 mRNA expression in normal human liver, in peritumoral livers, in liver cirrhosis in HCC and in  CCC Figure 5
Quantitative analysis of Prox1 mRNA expression in normal human liver, in peritumoral livers, in liver cirrhosis 
in HCC and in CCC. (A). Steady-state levels of Prox1 mRNA compared to the average expression of normal liver, which is 
displayed as 1. (B) Prox1 mRNA expression levels (normalised with the endogenous control) related to the average expression 
of normal liver compared with grading. (C) Northern blot analysis of Prox1 mRNA expression of individual HCC (left panel) 
and CCC (right panel) samples (upper images). The gel photos of total RNA are shown as loading references (lower images). 
The same individual samples are also marked on the graphs of A and B. (D) Western blot analysis of Prox1 protein in nuclear 
extracts of some individual samples of A-C, nuclear extract of HepG2 was used as a positive control.BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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described in Additional file 1. This mutation was located
in the prospero domain, at the C-terminus after the home-
odomain. The mutation changed Lys to Glu. In addition,
the analysed sequence contained more insertions and
deletions in the non-translated part (Additional file 1).
Databank evidence for more Prox1-mRNA-isoforms
The northern blot results were compared with Genebank
data. Based on recent database entries, different human
Prox1 mRNA isoforms are described. In the Vertebrate
Genome Annotation Database ("Human And Vertebrate
Analysis aNd Annotation", HAVANA) of the Sanger Insti-
tute (Cambridge, UK) two human Prox1 mRNAs are avail-
able, one consists of 7907, the other of 2929 bases.
Isoform-specific primer sets were designed for further
analysis of the two Prox1 mRNA isoforms. The primers
targeted the different exons of the two isoforms (Fig. 6).
Both, the 2929- and 7907-bases variants include the same
protein coding sequence. A major part of the last exon in
the 7907-bases-variant is not translated. Primers were
designed to the first exon of the 7907-bases variant, where
the forward primer reacted with the first part of the
untranslated exon-1, and the reverse primer was located in
exon-2 (Additional file 1). Primers were designed to a
similar position of exon 1–2 of "Prox1-2929". The for-
ward-primer reacted with an untranslated region of exon-
1 of "Prox1-2929"mRNA, while the reverse primer was the
same as by the 7907-base variant (Additional file 1). It is
clear from the Additional file 1 that, the first exons of the
Table 2: Change in Prox1-mRNA-expression compared with the average of normal liver, in all analysed samples.
Upregulated % (n) Not changed % (n) Downregulated % (n)
Normal liver 50 % (2) - 50 % (2)
Cirrhosis 55.54 % (6) 9.09 % (1) 36.36 % (4)
HCC 31.57 % (6) 15.78 % (3) 52.36 % (10)
Peritumoral (HCC), non-cirrhotic liver 50 % (2) 25 % (1) 25 % (1)
Peritumoral (HCC), cirrhotic liver 60 % (3) - 40 % (2)
CCC 37.5 % (3) 12.5 % (1) 50 % (4)
Peritumoral (CCC), non-cirrhotic liver 28.57 % (2) 14.28 % (1) 57.17 % (4)
Prox1 mRNA isoforms Figure 6
Prox1 mRNA isoforms. Scheme of the exon-intron construction of Prox1-mRNA-isoforms.BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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two isoforms of Prox1 contain different sequences. Never-
theless, these different regions are not translated.
Further analysis was performed on the other side of the
Prox1-mRNA-sequence, regarding the last exon. The
"Prox1-end" primer set amplified a sequence starting at
Exon 4, and finishing at Exon 5 of "Prox1-7907". The for-
ward primer included base pairs before and after Intron
4–5 to pick up transcribed gene only and to avoid picking
up genomic DNA. The reverse primer included an
AATAAA sequence [in mRNA AAUAAA], which is the sig-
nal for polyadenylation (Additional file 1) [30,31].
In the analysed liver samples the mRNA isoforms, which
were described in the databank, were confirmed by RT-
PCR-amplification and subsequent gel-electrophoresis,
and also by sequencing.
In the majority of the HCC samples the specific primers
for the last exon of the 7907 bases isoform, amplified the
1166-bases PCR product (not shown). In CCC samples
the same primers amplified a PCR product with less effi-
ciency, showing less or no product in several cases, or
unspecific bands (not shown). In both HCC and CCC the
first exons of both of the 7907 and of the 2929 bases iso-
forms were detected (not shown).
Possible regulation of the prox1-gene-expression
"In silico" analyses of the 5'-flanking sequences of Prox1
isoforms, revealed binding sites for different transcription
factors.
In the 5'-flanking sequence of the "7907-Prox1" among
others the consensus binding sequences of N-Myc and
Myc-associated Zinc-Finger (MAZ) were identified. Inter-
estingly, in contrast to N-Myc, MAZ-expression was
detected in all analysed liver samples (Fig. 7A, Table 3),
and cell lines (Table 4). While normal and peritumoral
non-cirrhotic liver, cirrhosis and CCC showed a similar
MAZ expression (p = 0.3112, by one-way ANOVA), signif-
icantly increased expression could be found in HCC (p =
10-4, by one-way ANOVA), (Fig. 7A, Table 3). MAZ-gene-
expression was upregulated in 78.94 % of the HCC sam-
ples, compared to the average of the normal liver (Table
3). In the 5'-flanking sequence of the "2929-Prox1" bind-
ing sites for several transcription factors were found (i. e.
cAMP-responsive Element Binding Protein (CREB) and
Activator protein 4 (AP-4)). Although, the mRNA expres-
sion of these genes was recognised, no significant change
was seen in the expression in liver cirrhosis, HCC and
CCC compared with normal human liver (p = 0.38; 0.144
for AP-4 and CREB, respectively, with one-way ANOVA),
(not shown).
Using EMSA, a significant binding was found to the MAZ-
consensus site-containing the 5'-flanking sequences of the
"Prox1-7902" transcript, in the cell nuclear extracts of
HCC cell lines, of Mz-Cha2 cell line and of a HCC tumor
sample. This binding capacity was suppressed by the 100-
fold excess of the MAZ-consensus oligo [23] (Fig. 7B). The
presence of the MAZ transcription factor in the cell
nuclear extract of a HCC cell line (Hep3B) was further
confirmed by a supershift assay, using a MAZ-specific goat
polyclonal antibody (Fig. 7C).
Following siRNA transfection in HepG2 cells, the MAZ
mRNA expression was reduced to 8.38% of the control,
while transfection with siRNA for cyclophilin B did not
cause suppression of MAZ mRNA. Interestingly, following
siRNA-mediated inhibition of MAZ mRNA expression,
the expression level of Prox1 was significantly reduced (p
= 0.03, with Student's t-test) to 41.72 % of the control
(Table 5). These data indicate the positive regulatory
potential of MAZ in the Prox1-gene-expression of HCC.
Discussion
Up to now the main function of Prox1 in the liver is not
well known. Previously we found that, Prox1 is expressed
in hepatocytes of normal and injured rat livers, whereas it
is absent in biliary epithelial cells [9,10].
Furthermore, we have studied the effects of Prox1 on the
transcriptional profile of met-murine hepatocytes
(MMH). These immortalized murine hepatoblasts express
numerous hepatoblast markers, but not Prox1. A stable
transfection with Prox1 cDNA and transcriptome analy-
ses, revealed an up-regulation of 22 genes and down-reg-
ulation of 232 genes. Many of these genes are involved in
hepatocyte functions, suggesting that Prox1 is a multi-
functional regulator of liver morphogenesis and of hepa-
tocyte function [32]. Proliferation of MMH was not
altered by stabile transfection with Prox1 [32].
Other researchers suggested a tumor suppressor function
for Prox1 [12,13] in HCC and CCC, and recently also in
other tumors [33].
In the current study we could detect a high variability of
Prox1 mRNA expression among normal, cirrhotic human
liver specimens, in HCC and in CCC. No significant rela-
tionship was found between Prox1 mRNA expression and
differentiation grade.
The prox1 gene is located on the long arm of chromosome
1 (1q32), where a loss of heterozygosity in malignant
lymphoma was observed [34]. This is an instable region of
the genome. Accordingly, we found a point mutation in
the prospero domain in one HCC sample with unex-
pected high Prox1 expression. This mutation might elim-BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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inate or alter the function of the prox1 gene [35]. Similarly
to previously described mutations [35], this mutation also
occurred at evolutionary conserved codons [36].
Our findings indicated that, apart from hepatocytes,
Prox1-expression was also detectable in ductular cells
within the fibrotic septa of cirrhotic livers and in the
nuclei of intrahepatic cholangiocellular carcinoma cells.
mRNA expression of MAZ in normal human liver, in peritumoral liver, in liver cirrhosis, in HCC and in CCC, MAZ-binding to  the Prox1 promoter Figure 7
mRNA expression of MAZ in normal human liver, in peritumoral liver, in liver cirrhosis, in HCC and in CCC, 
MAZ-binding to the Prox1 promoter. (A) mRNA expression levels of MAZ in normal human liver, in non-cirrhotic peri-
tumoral liver, in liver cirrhosis, in cirrhotic peritumoral liver, in HCC and in CCC compared to the average expression of nor-
mal liver, which is displayed as 1. HCC displayed a significant upregulation, marked with asterisk. The same individual samples 
are marked as the ones on Fig. 5. (B) EMSA reaction of cell nuclear extracts of HepG2 (2), Hep3B (3) and Mz-Cha2 (4), cell 
lines, and of nuclear extracts of HCC (5–6) and CCC samples (7) incubated for 30 minutes with the MAZ-consensus binding 
oligo-containing 5'-flanking sequence of the "Prox1-7902"-transcript (Fig. 1) (left panel). When the nuclear extracts were 
reacted with the same radiolabelled consensus double-stranded oligo in the presence of a 100-fold excess of an unlabeled 
MAZ-consensus oligo (published in ref. [23]) the intensity of mobility shift significantly decreased (right panel); sample 1: nega-
tive control, without nuclear extract. (C) EMSA reaction of cell nuclear extracts of Hep3B (2–3) cells incubated for overnight 
with the MAZ-consensus binding oligo-containing 5'-flanking sequence of the "Prox1-7902"-transcript, without (2) and with (3) 
anti-MAZ antibody; sample 1: negative control, without nuclear extract. The strong unspecific band might represent other 
transcription factors binding to the same sequence. In the presence of the anti-MAZ antibody a supershift band was observed 
(lane 3).BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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In order to identify Prox1+ cells in the investigated human
liver samples, lineage-specific markers were used.
HepPar1 was described as a hepatocyte marker [24] and
was also observed in liver cells with intermediate fate
(hepatocyte/cholangiocyte) in a variety of acute and
chronic human liver diseases [24,37-39]. CK7, CK19 and
OV-6 biliary type cytokeratins have been described in
"oval cells" as well [26,40]. OV-6 is a monoclonal anti-
body rose against cells isolated from 2-acetylaminoflu-
orene-treated rat liver, which recognize the epitope on
cytokeratins (CK) 19 and 14, and is a widely used "oval
cell" marker [27,28,38,41].
Cells of morphology and immunophenotype intermedi-
ate between hepatocytes and cholangiocytes ("intermedi-
ate cells") were not recognized in normal liver tissue [42].
Surprisingly, ductular cells, which were positive for biliary
epithelial cell markers (CK7, CK19, OV-6) [42] and
located within the fibrotic septa and at the margin of
regenerating nodules of cirrhotic livers, showed a positive-
staining for Prox1 as well. Morphologically, these cells
were different from hepatocytes and had features shared
with biliary epithelial cells (small oval to cuboidal cells
with round to oval nuclei). These findings support that
Prox1+ cells of CCC might descend from the biliary epi-
thelial cell lineage, and Prox1 is newly expressed in those
cells.
The current study provided data, which might take an
insight into the regulation of Prox1 expression under
pathological conditions. This study confirmed the exist-
ence of more mRNA isoforms, which was shown by
Zinovieva et al., in 1996 [36]. In this study two isoforms
were revealed by hybridisation and sequencing. In the
previous report of Zinovieva et al. (1996) [36] an addi-
tional unclear hybridisation smear was observed between
the long and the short transcript in the human embryonic
lens samples. Similarly, on our Fig. 5C unclear hybridisa-
tion results were observed in more samples. These obser-
vations indicate the existence of more Prox1 transcripts,
which were discovered more than 20 years ago. Identifica-
tion of even more Prox1 mRNA transcript might be
expected in the future. These isoforms might be regulated
by different regulatory sequences, but the same sequences
might influence more isoforms based on their position
(OTTHUMG00000036946 in the VEGA database). The
dominance of the 7907 bases form was found in more
hepatocellular carcinoma samples, while the shorter iso-
form was more often dominant in CCC (Fig. 5C), and in
the MZ-Cha2 biliary adenocarcinoma cell line. The induc-
tion of the shorter Prox1 mRNA isoform might be related
with a neoexpression in a cell population with biliary phe-
notype in liver cirrhosis and in CCC.
The results of the current work suggest that in HCC the
Myc-associated Zinc-finger protein (MAZ) might be
involved in the expression Prox1. The expression of MAZ
is significantly increased in HCC. It was demonstrated
here that, the MAZ protein might directly bind to respon-
sive elements included in the regulatory sequences of
Prox1, and might contribute to the positive regulation of
this gene (Fig 7, Table 5). MAZ was originally found to
bind specifically to the wild-type ME1a1 sequence, a 16-
base-pair nuclear factor binding site residing between the
c-myc P1 and P2 transcription initiation sites, the MElal
site facilitate initiation from the downstream start site of
c-myc [43]. Northern blot analysis revealed that MAZ is
expressed in human heart, brain, placenta, lung, liver,
skeletal muscle, and pancreas [43]. It was shown that co-
expression of c-myc and transforming growth factor
(TGF)-alpha as transgenes in mouse liver results in major
enhancement of neoplastic development [44]. C-myc
contributes to hepatocarcinogenesis not only by regulat-
ing cell proliferation and death but more profoundly by
modulating specific metabolic pathways [45]. Based on
the current study, MAZ might be involved also in the reg-
ulation of Prox1 in HCC. Prox1 might influence several
genes involved in hepatic metabolic functions [32].
Table 3: Change in MAZ-mRNA-expression compared with the average of normal liver, in all analysed samples.
Upregulated % (n) Not changed % (n) Downregulated % (n)
Normal liver 25 % (1) 25 % (1) 50 % (2)
Cirrhosis - - 100 % (11)
HCC 78.94 % (15) 5.26 % (1) 15.78 % (3)
Peritumoral (HCC), non-cirrhotic liver 50 % (2) 50 % (2)
Peritumoral (HCC), cirrhotic liver 40 % (2) - 60 % (3)
CCC 50 % (4) - 50 % (4)
Peritumoral (CCC), non-cirrhotic liver 28.57 % (2) 42.85 % (3) 28.57 % (2)
Table 4: Typical Ct-Values of the real-time RT-PCR for MAZ-
expression in HCC and CCC cell lines.
HepG2 24.32
HuH7 24.64
Hep3B 23.34
SK-Cha1 25.17
MZ-Cha1 24.31
MZ-Cha2 24.05BMC Cancer 2008, 8:92 http://www.biomedcentral.com/1471-2407/8/92
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The Prox1 isoforms not only differ by their 5'-flanking
regions, but also by their end-sequence. In the 3'-non-
translated area the unprocessed pre-mRNA contains a sig-
nificant signal-motive, which functions as a signal for
polyadenylation, recognised by Cleavage and Polyadenyla-
tion Specificity-Factor (CPSF) [30,31] Although alternative
sequences also exist, the AAUAAA is the most wide-spread
polyA signal. AAUAAA is detectable after the TGA stop
codon in the "Prox1-7907", but not in the "Prox1-2929".
This difference might be related with a higher stability of
the "Prox1-7907", which dominates over the short iso-
form in HCC. Accordingly, MAZ might be also involved in
transcriptional stabilisation, not only in initialisation of
the transcription [43].
Conclusion
In summary, the current study provided further evidence
for the existence of different Prox1 mRNA isoforms in
human liver, and recognised the dominance of a 7907-
bases isoform in HCC, and the 2929-bases isoform in
CCC. In some HCC cases the Prox1 mRNA expression was
higher compared to the average of the normal liver, which
in one case was related with mutation. At protein level the
expression of the 95 kD protein was lower in liver tumors,
or degradation was detected in the cell nuclear extracts.
Human HCC cell lines contained high Prox1 expression
both at protein and mRNA levels. The expression of the
"Prox1-7907"-mRNA-isoform, and the high expression of
Prox 1 in HCC cell lines might be associated with the
increased expression of MAZ transcription factor, which is
able to bind to the promoter of "Prox1-7907". A direct lin-
ear relationship between MAZ and Prox1 expressions
could not be stated. Our histological analysis detected the
neoexpression of Prox1-protein in ductular biliary cells of
liver cirrhosis and of CCC.
Although our understanding is continuously increasing,
there are still several puzzles and contradictions related to
this homeobox gene in hepatic carcinogenesis, which
should be solved in the future.
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